Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Rep
Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycard
Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycard